SCHEMBL4649903

SCHEMBL4649903

O=S(=O)(c1ccccc1)c1cnc2c(O[C@H]3CCNC3)cccc2c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.53
HTR6 P50406 3/20 0.53
HTR2A P28223 2/20 0.53
DRD2 P14416 1/20 0.53
HTR7 P34969 1/20 0.53
PIM1 P11309 3/20 0.43
PIM2 Q9P1W9 3/20 0.43
SLC6A2 P23975 2/20 0.40
HTR2B P41595 5/20 0.40
HTR2C P28335 4/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
IKBKB O14920 2/20 0.38
CHUK O15111 2/20 0.38
PRKCZ Q05513 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4649526 1.00 HTR1A (0.53) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4649524 1.00 HTR1A (0.53) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4649236 0.94 HTR1A (0.52) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4648947 0.94 HTR6 (0.58) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4650645 0.81 HTR6 (0.54) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4650003 0.80 HTR6 (0.51) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4649908 0.80 HTR6 (0.51) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4756585 0.80 HTR6 (0.51) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4650016 0.79 PRKCZ (0.49) HTR1AHTR6HTR2ADRD2HTR7
SCHEMBL4650000 0.78 HTR2A (0.48) HTR1AHTR6HTR2ADRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730112-B1 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LTD (GB) 2008-09-03 EP claimed
EP-1904500-A1 NEW DERIVATIVES OF HEPTAAZAPHENALENE, METHODS FOR OBTAINING THEM, AND THEIR USE AS PROTECTING AGENTS AGAINST UV RADIATION ISDIN, S.A. (ES) 2008-04-02 EP claimed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US claimed
WO-2007006807-A1 NEW DERIVATIVES OF HEPTAAZAPHENALENE, METHODS FOR OBTAINING THEM, AND THEIR USE AS PROTECTING AGENTS AGAINST UV RADIATION ISDIN, S.A. (ES) 2007-01-18 WO claimed
EP-1730112-A1 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2006-12-13 EP claimed
WO-2005095346-A1 3-((HETERO)ARYLSULFONYL)-8-` (AMINOALKYL)OXY!QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2005-10-13 WO claimed
EP-1730112-B1 3-((HETERO)ARYLSULFONYL)-8'[ (AMINOALKYL)OXY]QUINOLINES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LTD (GB) 2008-09-03 EP disclosed
EP-1904500-A1 NEW DERIVATIVES OF HEPTAAZAPHENALENE, METHODS FOR OBTAINING THEM, AND THEIR USE AS PROTECTING AGENTS AGAINST UV RADIATION ISDIN, S.A. (ES) 2008-04-02 EP disclosed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US disclosed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US disclosed
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders GLAXO GROUP LIMITED (GB) 2007-08-16 US disclosed
WO-2007006807-A1 NEW DERIVATIVES OF HEPTAAZAPHENALENE, METHODS FOR OBTAINING THEM, AND THEIR USE AS PROTECTING AGENTS AGAINST UV RADIATION ISDIN, S.A. (ES) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191345-A1 3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders HTR6, HTR3B, HTR2C HTR1A 7/4885HTR6 1/4885HTR2A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.